Magnesium
Riboflavin
Feverfew
Ingredients
Recommended Usage
Contraindications, Adverse Reactions or Drug Interactions
Selected References

MigreLief is a patented combination (patents 6,068,999 and 6,500,450) of 3 natural ingredients, which multiple, double-blind, placebo controlled clinical studies published in top medical journals have shown can affect migraine frequency and intensity*.  It contains high dose:

Research studies show that almost half of all migraine sufferers have low blood levels of Magnesium—which is critical in controlling vasospasms (the contraction and dilation of blood vessels in the brain which occurs during migraines).  Migraine sufferers also suffer mitochondrial energy deficiencies, which Riboflavin (Vitamin B2) can improve when given in high dosages.  And the plant material Feverfew has been shown to reduce platelet aggregation, which can lead to vasoconstriction.  So all 3 ingredients have been recommended for years by many doctors and top headache specialists based on the clinical studies behind them.

MigreLief combines all 3 of these ingredients into one formula -- at the dosages the clinical studies show are beneficial.  So you take 1 product not 3 products.  And you take 2 tablets/day -- versus 4 - 10 tablets/day if taken separately.  Plus, MigreLief’s Puracol Feverfew contains high levels of parthenolides and other active components – which other feverfew products cannot guarantee.

See links to the left for more product information.

Magnesium

Magnesium is a nutritional supplement with numerous effects that support cerebrovascular tone. These include: 1) inhibition of platelet aggregation;2) interference with synthesis, release, and action of inflammatory mediators;3) direct alterations of cerebrovascular tone; 4) inhibition of vasospasm; and 5) stabilization of cell membranes. Some migraine sufferers with poor cerebrovascular tone have been found to have low brain levels of magnesium. Recommended daily dosages of magnesium typically range from 200 to 600 mg to compensate for this deficiency -- far above what's found in most multi-vitamins.

Riboflavin

Riboflavin (vitamin B-2) is a precursor of flavin adenine dinucleotide(FAD). This coenzyme is an important component of the electron-transport chain. A deficiency of mitrochondrial energy reserves has been observed in some persons exhibiting poor cerebrovascular tone. This defect may theoretically be corrected by a compound such as riboflavin that improves the activity of the electron-transport chain. MigreLief provides 400mg of Riboflavin -- significantly higher than most multi-vitamins or B-complex products.

Feverfew

Commonly recommended for its ability to support cerebrovascular tone, feverfew (Tanacetum parthenium) is rich in compounds known as sesquiterpene lactones. One of the more important of these compounds may be parthenolide, which represents 85% of the sesquiterpene lactone content in feverfew. Some scientific studies indicate that while parthenolide may be important there may very well be other phytochemicals in feverfew that are as of yet unidentified and play a role in its effectiveness. Some studies of extracts of feverfew containing parthenolide yielded no significant benefits. This led researchers to believe that certain of the unidentified phytochemicals may have been left behind during the extraction process. The ideal solution would be a non extracted feverfew product that naturally contained high levels of parthenolide and kept all of the other naturally occurring phytochemicals as well. Thus Puracol Feverfew, AKESO HEALTH SCIENCE'S proprietary non extracted plant source for feverfew with high levels of naturally occurring parthenolide was developed. Puracol Feverfew, is just one of the reasons for the superior efficacy of MigreLief which delivers optimal dosages of parthenolide. Scientific studies have found parthenolide inhibits platelet aggregation and the release of serotonin from platelets and polymorphonuclear leukocyte granules.* It has also been shown to inhibit pro-inflammatory prostaglandin synthesis and the release of arachadonic acid. Each of these phenomena are associated with migraines.* European studies have shown the benefits of feverfew on long-term cerebrovasular tone.

Ingredients

Two tablets Provide:

Puracol Feverfew(Tanacetum parthenium)
100 mg.

Magnesium (Citrate/Oxide 1:1)
360mg 75% of U.S. RDA*

Riboflavin (Vitamin B2)
400 mg 23,525% of U.S. RDA*

**Protected by U.S. Patent #6,068,999 and U.S. Patent # 6,500,450 B1

*Percentage of U.S. Recommended Daily Allowance Contains no yeast, milk, corn, wheat, gluten, soy sodium, salt, sugar,flavorings, preservatives, artificial colors. This product is not intended to diagnose, treat, cure or prevent any disease.

Recommended Usage

Take 1 tablet twice daily. MigreLief is designed to provide benefits within the 90 day build up period.  Continue daily use if you notice benefits.  MigreLief can be used with migraine prescription medicines or by itself.

Contraindications, Adverse Reactions or Drug Interactions

Side effects due to any of the ingredients in MigreLief are rare. Mild gastrointestinal upset and loose stools may occur in some persons using magnesium. People using a calcium and magnesium combination supplement may need to change to a calcium only supplement if gastrointestinal upset occurs.  A bright yellow colored urine is due to Vitamin B2, and is both normal and safe. This product is not recommended for use during pregnancy or lactation and should not be used in children under the age of two years. Persons taking potassium-sparing diuretics or with renal failure should not use this product.

Selected References

Brown D, Gaby A, Reichert R. Clinical Applications of Natural Medicine--Migraine. NPRC Condition-Specific Monograph Series, 1997.

Feverfew. Lawrence Review of Natural Products, September 1994.

Awang DVC. Herbal Medicine, Feverfew. Canadian Pharm J 1989; 122:266-70.

Heptinstall S, Awang DVC, Dawson BA, et al. Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium). Estimation of Commercial and Authenticated Feverfew Products. J Pharm Pharmacol 1992; 44:391-5.

Pugh WJ, Sambo K. Prostaglandin Synthetase Inhibitors in Feverfew. J Pharm Pharmacol 1988; 40-743-5.

Heptinstall S, White A, Williamson L, Mitchell JRA. Extracts of Feverfew Inhibit Granule Secretion in Blood Platelets and Polymophonuclear Leukocytes. Lancet 1985; i:1071-4.

Makheja AN, Bailey JM. A Platelet Phospholipase Inhibitor from the Medicinal Herb Feverfew (Tanacetum parthenium). Prostagland Leukotrienes Med 1982;8:653-60.

Sumner H, Salan U, Knight DW, Hoult JRS. Inhibition of 5-Lipoxygenase and Cyclo-oxygenase in Leukocytes by Feverfew. Biochem Pharmacol 1992;43:2313-20.

Johnson ES, Kadam NP, Hylands DM, Hylands PF. Efficacy of Feverfew As prophylactic Treatment of Migraine. British Med J 1985; 291:569-73.

Murphy JJ. Heptinstall S, Mitchell JRA. Randomized Double-Blind Placebo-Controlled Trial of Feverfew in Migraine Prevention. Lancet 1988; ii:189-92.

Altura BM. Calcium Antagonist Properties of Magnesium: Implications for Anti-migraine Actions. Magnesium 1985; 4:169-75.

Ramadan NM, Halvorson H, Vande-Linde A, et al. Low Brain Magnesium in Migraine. Headache 1989; 29:590-93.

Weaver K. Magnesium and Migraine. Headache 1990; 30:168.

Faccinetti F, Sances G, Borella P, et al. Magnesium Prophylaxis of Menstrual Migraine: Effects on Intra-cellular Magnesium. Headache 1991; 31:298-304.

Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of Migraine with Oral Magnesium: Results from a Prospective, Multi-Center, Placebo-Controlled and Double-Blind Randomized Study. Cephalalgia 1996; 16:257-63.

Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the Prophylaxis of Migraine--A Double-Blind, Placebo-Controlled Study. Cephalalgia 1996;16:436-40.

Schoenen J, Lenaerts M, Bastings E. High-dose Riboflavin as a Prophylactic Treatment of Migraine: Results of an Open Pilot Study. Cephalalgia 1994l14:328-9